统计剂诱导肌肉病的遗传决定因素:观察性研究的网络元分析
Kannan Sridharan1, Gowri Sivaramakrishnan2
1Department of Pharmacology & Therapeutics, College of Medicine & Medical Sciences, Arabian Gulf University, Manama, Kingdom of Bahrain.
概括
遗传变异,特别是在SLCO1B1基因中,显著增加了因他类药物引起的肌肉病变 (SIM) 的风险. 基因型定型SLCO1B1可以告知他类药物治疗决策,以改善患者的治疗结果.
科学领域:
- 药物基因组学 药物基因组学
- 临床药理学 临床药理学
- 药物不良反应 药物不良反应
背景情况:
- 类他类药物诱导肌肉病变 (SIM) 是一种常见的不良反应,减少了患者对他类药物治疗的坚持.
- 目前对影响SIM发病率的遗传因素的研究提出了相互矛盾的证据,需要进一步调查.
研究的目的:
- 进行网络元分析,以系统地评估遗传变异与他类药物诱导肌肉病的风险之间的关联.
- 识别预测SIM风险的特定基因和单核酸多态 (SNP).
主要方法:
- 进行了观察性研究的系统审查,包括服用他类药物的患者报告SNP和SIM.
- 严重的SIM被定义为肌酸激酶水平>正常的上限10倍.
- 混合治疗比较元分析被用来从直接和间接比较中汇集估计,并进行引导验证.
主要成果:
- 对34项研究 (26,152名参与者) 的分析显示,药物载体基因与SIM之间存在显著的关联 (OR:1.4).
- 溶解物载体有机离子载体1B1 (SLCO1B1) rs4149056多态表现出与SIM (OR:2.1) 的中度关联.
- 严重的SIM与SLCO1B1 rs4149056 (OR: 3.8) 和ATP绑定磁带子家族B成员1 (ABCB1) rs2373588 (OR: 2.8) 相关.
结论:
- 这项研究证实了SLCO1B1基因变异与SIM之间的显著关联,突出了其临床相关性.
- 这些发现支持目前的指导方针,建议SLCO1B1基因定型用于个性化他类药物治疗决策.
- 需要进一步的研究来确定SIM的其他遗传预测因子.
更多相关视频
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
475
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
475
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
21
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
21
Genome-wide Association Studies-GWAS
12.2K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.2K
Myasthenia Gravis: Diagnostic Tests
562
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
562


